<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ChinaCSR.com &#187; ACT</title>
	<atom:link href="http://www.chinacsr.com/en/tag/act/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.chinacsr.com/en</link>
	<description>Corporate Social Responsibility (CSR), Business Intelligence, and Sustainability News for China</description>
	<lastBuildDate>Tue, 07 Feb 2012 06:17:22 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Chinese Pharmaceutical Enterprise Signs Agreement With Clinton Foundation</title>
		<link>http://www.chinacsr.com/en/2008/07/28/2581-chinese-pharmaceutical-enterprise-signs-agreement-with-clinton-foundation/</link>
		<comments>http://www.chinacsr.com/en/2008/07/28/2581-chinese-pharmaceutical-enterprise-signs-agreement-with-clinton-foundation/#comments</comments>
		<pubDate>Sun, 27 Jul 2008 19:31:53 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[ACT]]></category>
		<category><![CDATA[artemisinin]]></category>
		<category><![CDATA[Clinton]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[HIV/AIDS Initiative]]></category>
		<category><![CDATA[Holleypharm]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[William J. Clinton Foundation]]></category>

		<guid isPermaLink="false">http://www.chinacsr.com/?p=2581</guid>
		<description><![CDATA[Holleypharm has signed an agreement for artemisinin with the William J. Clinton Foundation, agreeing to lower the price of a leading artemisinin-based combination therapy for malaria by 30% and reduce the price volatility of artemisinin, the key raw material for this and other ACTs, by 70%. According to the agreement, Holleypharm will regularly supply artemisinin [...]]]></description>
		<wfw:commentRss>http://www.chinacsr.com/en/2008/07/28/2581-chinese-pharmaceutical-enterprise-signs-agreement-with-clinton-foundation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

